Vaxcyte financials
$58.27+3.66%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$302.8M | -$345.9M | -$274.3M | -$242.4M | -$226.2M | -$180.8M | -$162.2M | -$139.9M | -$153.0M | -$114.5M | -$196.7M | -$113.0M |
| Net income | -$284.3M | -$320.6M | -$246.5M | -$212.8M | -$166.6M | -$140.7M | -$137.1M | -$103.1M | -$128.7M | -$95.0M | -$180.8M | -$92.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.97 | $-2.30 | $-1.81 | $-1.56 | $-1.22 | $-1.04 | $-1.01 | $-0.83 | $-1.10 | $-0.85 | $-1.76 | $-0.91 |
| EBITDA | -$299.8M | -$342.9M | -$258.3M | -$239.3M | -$223.3M | -$177.8M | -$150.5M | -$138.1M | -$151.6M | -$113.5M | -$121.7M | -$112.2M |
| Operating cash flow | -$232.5M | -$280.6M | -$224.8M | -$143.3M | -$121.2M | -$166.3M | -$111.4M | -$60.7M | -$121.4M | -$159.1M | -$128.8M | -$57.5M |
| Free cash flow | -$237.0M | -$295.4M | -$233.3M | -$155.4M | -$130.9M | -$193.0M | -$141.4M | -$98.8M | -$160.4M | -$171.2M | -$185.9M | -$64.9M |
| Diluted shares | 144.5M | 139.5M | 136.4M | 136.2M | 136.0M | 135.7M | 135.3M | 123.7M | 117.3M | 111.7M | 102.7M | 101.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $183.2M | $260.8M | $174.0M | $281.1M | $306.7M | $346.9M |
| Short-term investments | $1.30B | $1.48B | $1.39B | $1.43B | $1.35B | $1.32B |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.14B | $3.35B | $3.00B | $3.17B | $3.31B | $3.38B |
| Total liabilities | $380.2M | $352.3M | $317.2M | $278.7M | $234.0M | $178.1M |
| Shareholders' equity | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | $3.20B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology